An early warning system that helps busy doctors, nurses and other healthcare professionals to quickly identify when patients are at risk of deterioration is to be deployed across hospitals and community settings throughout Lanarkshire. 
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including a patient-preferred design without compromising battery longevity and MRI compatibility. 
The Highland Marketing advisory board has been discussing the impact of the coronavirus outbreak on the deployment of health tech in the NHS.
At its March meeting, which took place just after UK prime minister Boris Johnson instructed people to "stay at home", members noted the rapid roll-out of remote working and virtual consultation tools, which are unlikely to be abandoned once the emergency is over.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. 
Treating anxiety and depression with digital mental health therapy has a significant and long-term benefit for recovery, new research amongst NHS service users suggests. The research was undertaken by SilverCloud Health, the world's leading digital mental health company, with the School of Psychology at Trinity College, the University of Dublin, and health economics analysis from the University of Sheffield. 
The U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only game-based device, called EndeavorRx, is indicated for pediatric patients ages 8 to12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue. 
Dedalus Group, leader in Europe and one of the world's leading players in clinical and healthcare information systems supporting clinical professionals and healthcare facilities thanks to a wide portfolio of innovative products, has appointed Andrea Fiumicelli as CEO of the Group. 
